Efficacy of secukinumab in treating psoriasis The interleukin-17A (IL-17A) inhibitor secukinumab shows promise as a treatment option for patients with moderate to severe psoriasis Sign in to continue Sign In Email address Password Stay signed in Trouble signing in? Reset password: Click here Need help? Email us Register FREE Limited free articles a month Free email bulletins Register Now Subscribe now Benefits include: Full site access Subscriber exclusive content Exclusive bulletins Choose a package